Shares in Tokyo-listed Takeda tumbled yesterday after it raised its offer for Irish pharmaceutical company Shire to £46 billion (US$64 billion), which would represent the largest-ever foreign takeover by a Japanese firm.
Shire was “willing to recommend the revised proposal to Shire shareholders subject to satisfactory resolution of the other terms of the possible offer,” the London-listed company said.
The latest bid follows a string of lower offers rejected by Shire over the past month.
It comes as Takeda looks to expand abroad in the face of an expected drug price drop at home.
The buyout would be a smart move for Takeda as it looks to diversify, and could pay off in the long-term, analysts said.
However, the news sent Takeda shares plunging more than nine percent in Tokyo at one point in the morning, with investors worried it would overextend the firm’s finances. At the close it was down 7.02 percent to ¥4,510, while Shire opened in London trade up 2.80 percent at £40.40.
Shire, in a statement on Tuesday night set a new May 8 deadline for the conclusion of negotiations.
The offer is equivalent to £49 a share, Shire said, and represents a 60 percent premium to its closing price on March 27, before Takeda made its interest known.
Shire said that on completion of the deal, shareholders would own about 50 percent of the enlarged Takeda, while the new Takeda shares would be listed in Japan and the US.
Shire on Friday last week rejected Takeda’s fourth offer in a month, worth £42.8 billion, saying it was too low.
Botox maker Allergan last week said it was considering making a counteroffer for Shire, raising the prospect of a bidding war, but then confirmed it would not go ahead.
The buyout is the latest in a flurry of merger and acquisition activity in the pharmaceutical industry as traditional players see profits eroded by competition from generic medicines.
Japanese drugmakers in particular are facing pressure in the domestic market as the government tries to cut prices of many branded medicines and increase the focus on cheaper generics to curb health spending as the population ages rapidly.
Takeda, led by Christophe Weber, has been actively looking overseas for acquisitions.
In 2011, it took over Swiss rival Nycomed for 9.6 billion euros (US$13.6 billion at the time).
Notwithstanding the negative initial market reaction, the takeover would likely be good for Takeda, Rakuten Securities chief strategist Masayuki Kubota said.
“It would be the biggest-ever takeover by a Japanese company and it’s natural for that to spawn worries” because a failed buyout could cause huge losses, he said.
However, Shire offered an attractive portfolio, Kubota added.
“They have a lot of treatments for rare diseases, where the barriers to entry for other companies are very high. Their profitability is high,” he said.
Takeda is right to take advantage of its ample cash flow and Japan’s low interest rates, Kubota said. “It may look expensive short-term, but it will bring good benefits over the longer term,” he said.
“It would also enhance its global reach,” Credit Suisse analyst Fumiyoshi Sakai said, adding that it would give Takeda access to “research and development in the field of digestive systems, mental illness and rare diseases where Takeda has wanted collaboration.”
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has appointed Rose Castanares, executive vice president of TSMC Arizona, as president of the subsidiary, which is responsible for carrying out massive investments by the Taiwanese tech giant in the US state, the company said in a statement yesterday. Castanares will succeed Brian Harrison as president of the Arizona subsidiary on Oct. 1 after the incumbent president steps down from the position with a transfer to the Arizona CEO office to serve as an advisor to TSMC Arizona’s chairman, the statement said. According to TSMC, Harrison is scheduled to retire on Dec. 31. Castanares joined TSMC in
EUROPE ON HOLD: Among a flurry of announcements, Intel said it would postpone new factories in Germany and Poland, but remains committed to its US expansion Intel Corp chief executive officer Pat Gelsinger has landed Amazon.com Inc’s Amazon Web Services (AWS) as a customer for the company’s manufacturing business, potentially bringing work to new plants under construction in the US and boosting his efforts to turn around the embattled chipmaker. Intel and AWS are to coinvest in a custom semiconductor for artificial intelligence computing — what is known as a fabric chip — in a “multiyear, multibillion-dollar framework,” Intel said in a statement on Monday. The work would rely on Intel’s 18A process, an advanced chipmaking technology. Intel shares rose more than 8 percent in late trading after the